CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 24 enrolled
Drug / intervention
HB-adMSCs +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05116540
NCT05116540Phase 2Completed
CompareCT.gov

A Randomized, Double-Blind, Single-Center, Phase 2, Efficacy and Safety Study of Autologous HB-adMSCs vs Placebo for the Treatment of Patients With Multiple Sclerosis

Hope Biosciences Research Foundation·interventional·Posted Nov 11, 2021·Updated Sep 26, 2025

In Brief

A Phase 2 clinical trial evaluating HB-adMSCs and Placebo for Multiple Sclerosis. Completed, enrolled 24 participants across 1 site.

Detailed Summary

Randomized Double-Blind Efficacy and safety study of Autologous HB-adMSCs versus placebo for the treatment of Multiple Sclerosis. This study will be for 24 subjects with 6 infusions over a 52 week period. Study participants will continue their established concomitant medications during participation in this investigation.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20222023202420252026
First PostedNov 11, 2021
Enrollment StartNov 24, 2021
Primary CompletionJun 4, 2024
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 4.6 years ago

Interventions

HB-adMSCsbiological

Autologous product

Placebodrug

Normal Saline